Structure-based inhibitor design and validation: Application to Plasmodium falciparum glutathione S-transferase Marli Botha MSc. Bioinformatics.

Slides:



Advertisements
Similar presentations
Miroslav Brumovský28th July 2011 Miroslav Brumovský 28 th July 2011 Methods using polarization for in silico fragment-based drug design.
Advertisements

AutoDock 4 and AutoDock Vina -Brief Intruction
Jürgen Sühnel Institute of Molecular Biotechnology, Jena Centre for Bioinformatics Jena / Germany Supplementary Material:
Molecular dynamics refinement and rescoring in WISDOM virtual screenings Gianluca Degliesposti University of Modena and Reggio Emilia Molecular Modelling.
INFSO-RI Enabling Grids for E-sciencE WISDOM mini-workshop Vincent Breton (CNRS-IN2P3, LPC Clermont-Ferrand) ISGC 2007 March 28th,
Establishing a Successful Virtual Screening Process Stephen Pickett Roche Discovery Welwyn.
BL5203: Molecular Recognition & Interaction Lecture 5: Drug Design Methods Ligand-Protein Docking (Part I) Prof. Chen Yu Zong Tel:
1111 Discovery Novel Allosteric Fragment Inhibitors of HIV-1 Reverse Transcriptase for HIV Prevention A/Prof Gilda Tachedjian Retroviral Biology and Antivirals.
Protein-protein and Protein- ligand Docking The geometric filtering.
Chemoinformatics in Drug Design
Doug Brutlag 2011 Genomics, Bioinformatics & Medicine Drug Development
Bioinformatics Ayesha M. Khan Spring Phylogenetic software PHYLIP l 2.
Important Points in Drug Design based on Bioinformatics Tools History of Drug/Vaccine development –Plants or Natural Product Plant and Natural products.
GGAGATTCTGGGCCACTTTGGTTCCCCATGAGCCAAGACGGCACTTCTAATTTGCATTCCCTACCGGAGTCCCTGTCTGTAGCCAGCCTGGCTTTCAGCTGGTGCCCAAAGTGACAAATGTATCTGCAATGACAAAGGTAC CCTGGAAGGGCTCGCCCTCTGCGGAATTTCAGTTCATGCAGGCCTTGGTGCTTCCACATCTGTCCAAGGGCCTTTCAAATGTGACTTTTAACTCTGTGGATTGATTTGCCCGG
Computational Techniques in Support of Drug Discovery October 2, 2002 Jeffrey Wolbach, Ph. D.
Computer-Assisted Drug Design (1) i)Random Screening ii)Lead Development and Optimization using Multivariate Statistical Analyses. iii)Lead Generation.
NUS CS5247 A dimensionality reduction approach to modeling protein flexibility By, By Miguel L. Teodoro, George N. Phillips J* and Lydia E. Kavraki Rice.
Asia’s Largest Global Software & Services Company Genomes to Drugs: A Bioinformatics Perspective Sharmila Mande Bioinformatics Division Advanced Technology.
Rational Drug Design Soma Mandal, Mee'nal Moudgil, Sanat K. Mandal.
FKPPL workshop May 2012 BUI The Quang Prof. Vincent Breton Prof. Doman Kim Prof. NGUYEN Hong Quang Prof. PHAM Quoc Long Grid enabled in silico drug discovery.
Identification of New Inhibitors of Plasmodium falciparum Enoyl- ACP Reductase Symposium on: Advances in Parasitology “Education and Research in Parasitology.
Application of e-infrastructure to real research.
DE NOVO DESIGN OF A THYMIDYLATE KINASE INHIBITOR.
Protein Molecule Simulation on the Grid G-USE in ProSim Project Tamas Kiss Joint EGGE and EDGeS Summer School.
INFSO-RI Enabling Grids for E-sciencE V. Breton, 30/08/05, seminar at SERONO Grid added value to fight malaria Vincent Breton EGEE.
Function first: a powerful approach to post-genomic drug discovery Stephen F. Betz, Susan M. Baxter and Jacquelyn S. Fetrow GeneFormatics Presented by.
In silico discovery of inhibitors using structure-based approaches Jasmita Gill Structural and Computational Biology Group, ICGEB, New Delhi Nov 2005.
Page 1 SCAI Dr. Marc Zimmermann Department of Bioinformatics Fraunhofer Institute for Algorithms and Scientific Computing (SCAI) Grid-enabled drug discovery.
SimBioSys Inc.© Slide #1 Enrichment and cross-validation studies of the eHiTS high throughput screening software package.
Samudrala group - overall research areas CASP6 prediction for T Å C α RMSD for all 70 residues CASP6 prediction for T Å C α RMSD for all.
INFSO-RI Enabling Grids for E-sciencE In silico docking on EGEE infrastructure, the case of WISDOM Nicolas Jacq LPC of Clermont-Ferrand,
Altman et al. JACS 2008, Presented By Swati Jain.
EGEE-II INFSO-RI Enabling Grids for E-sciencE WISDOM in EGEE-2, biomed meeting, 2006/04/28 WISDOM : Grid-enabled Virtual High Throughput.
Bioinformatics MEDC601 Lecture by Brad Windle Ph# Office: Massey Cancer Center, Goodwin Labs Room 319 Web site for lecture:
INFSO-RI Enabling Grids for E-sciencE EGEE Review WISDOM demonstration Vincent Bloch, Vincent Breton, Matteo Diarena, Jean Salzemann.
Molecular dynamics simulations of toxin binding to ion channels Quantitative description protein –ligand interactions is a fundamental problem in molecular.
Discovery of Therapeutics to Improve Quality of Life Ram Samudrala University of Washington.
Surflex: Fully Automatic Flexible Molecular Docking Using a Molecular Similarity-Based Search Engine Ajay N. Jain UCSF Cancer Research Institute and Comprehensive.
COMPUTATIONAL ENGINEERING OF BIONANOSTRUCTURES RAM SAMUDRALA ASSOCIATE PROFESSOR UNIVERSITY OF WASHINGTON How can we design peptides and proteins capable.
Elon Yariv Graduate student in Prof. Nir Ben-Tal’s lab Department of Biochemistry and Molecular Biology, Tel Aviv University.
Docking and Virtual Screening Using the BMI cluster
Molecular Modeling in Drug Discovery: an Overview
TIDEA Target (and Lead) Independent Drug Enhancement Algorithm.
HP-SEE In the search of the HDAC-1 inhibitors. The preliminary results of ligand based virtual screening Ilija N. Cvijetić, Ivan O. Juranić,
1st EELA-2 Grid School 2-15 November Jérôme Verleyen Juan Manuel Hurtado Rámirez Enrique Merino Pérez META-DOCK.
Structural Bioinformatics Elodie Laine Master BIM-BMC Semester 3, Genomics of Microorganisms, UMR 7238, CNRS-UPMC e-documents:
Page 1 Computer-aided Drug Design —Profacgen. Page 2 The most fundamental goal in the drug design process is to determine whether a given compound will.
Computational Evaluation of 22 identified malaria Drug targets
Computational Docking Experiments to Find a Ligand that Will Bind to Xanthine Oxidase Lysengkeng Her and Thao Yang Department of Chemistry, University.
SEMINAR 1. Title : Discovery of Protein-Protein Interaction Modulators Using Affinity-Based High-Throughput Screening 2. Speaker : Hyun-Suk Lim (포항공대 (POSTECH))
ATOM Accelerating Therapeutics for Opportunities in Medicine
APPLICATIONS OF BIOINFORMATICS IN DRUG DISCOVERY
Important Points in Drug Design based on Bioinformatics Tools
DATA MINING FOR SMALL MOLECULE ALLOSTERIC INHIBITORS
Discovery and Development of Medicines
WISDOM-II, status of preparation
Molecular Docking Profacgen. The interactions between proteins and other molecules play important roles in various biological processes, including gene.
Richard S. L. Stein CS 379a March 14, 2006
Virtual Screening.
“Structure Based Drug Design for Antidiabetics”
Insight into the Pharmaceutical Industry
An Integrated Approach to Protein-Protein Docking
Alexey Sulimov, Ekaterina Katkova, Vladimir Sulimov,
Drug Design and Drug Discovery
Cheminformatics Basics
Volume 84, Issue 4, Pages (April 2003)
Mr.Halavath Ramesh 16-MCH-001 Dept. of Chemistry Loyola College University of Madras-Chennai.
Mr.Halavath Ramesh 16-MCH-001 Dept. of Chemistry Loyola College University of Madras-Chennai.
Mr.Halavath Ramesh 16-MCH-001 Dept. of Chemistry Loyola College University of Madras-Chennai.
Mr.Halavath Ramesh 16-MCH-001 Dept. of Chemistry Loyola College University of Madras-Chennai.
Presentation transcript:

Structure-based inhibitor design and validation: Application to Plasmodium falciparum glutathione S-transferase Marli Botha MSc. Bioinformatics

Marli Botha © CSIR Background Structure-based inhibitor design and validation: Application to Plasmodium falciparum glutathione S-transferase Primary aim was to use a computational structure- based ligand design strategy to find novel ligands that can act as inhibitors to form the basis of future antimalarial drug development.

Marli Botha © CSIR A rational drug design strategy should be based on a validated target protein. With a proven relationship between its activity and the disease. The 3D structural information of the target protein should be available. X-ray or nuclear magnetic resonance (NMR) diffraction usually produces these structures. Preferably with a bound inhibitor. Structure-based inhibitor design

Marli Botha © CSIR Structure of the PfGST glutathione S- transferase active site with the bound inhibitor S-hexyl glutathione. The hydrogen interaction that is used by the substrate and substrate inhibitor (S-hexyl glutathione).

Marli Botha © CSIR Structure-based ligand design Newlead LUDI

Marli Botha © CSIR Structure of glutathione with fragments encircled that were used by NEWLEAD as building blocks to form new ligands. For NEWLEAD to function pharmacophore fragments have to be defined, the pharmacophore fragments defined for glutathione are the atoms encircled in various colors. LUDI uses potential interaction points on the receptor and then suggest modifications to the current ligand. Addition or replacement sites have to be supplied to the LUDI program. For GTX this was defined as indicated by the blue circles. Structure-based ligand design Newlead LUDI

Marli Botha © CSIR Structure-based inhibitor design and validation: Application to Plasmodium falciparum glutathione S-transferase In silico assessment and implementation of different ligand docking, scoring and design software to assemble a focused library of hypothetical inhibitory ligands of PfGST.

Marli Botha © CSIR Computer-based screening by docking and scoring Molecular docking: provided with the atomic coordinates of a receptor, the docking algorithm should be able to correctly predict the bound association between receptor and the ligand. Scoring functions: algorithm used to rank the docked poses or compare the affinity of different ligands for the same receptor (Perola et al., 2004).

Marli Botha © CSIR Docking program validation

Marli Botha © CSIR Protein binding affinity determination using consensus scoring Performance of scoring functions can be improved by using different scoring functions that estimate different properties. Although these scores have different scales, the average or summing of ranks should increase the discriminative ability of the scoring function (Clark et al., 2002). AutoDock provides an estimate of binding free energy in kcal/mol. LUDI provides a score that can be related to an inhibition constant (LUDI score 100 ≈ Ki of 100 mM). XScore provides an atomic binding score in pKd units that is related to the binding affinity.

Marli Botha © CSIR ● In order to gain trust in computer-based inhibitor design, as well as the method of affinity prediction, it is necessary to test some of these designed inhibitors experimentally. ● These results can be used as guidelines to optimize and improve this structure-based design protocol for further use. ● If this strategy proves to be successful, it can reduce the cost and time of future antimalarial drug development.

Marli Botha © CSIR Structure-based inhibitor design and validation: Application to Plasmodium falciparum glutathione S-transferase Exploring the relationship between the in silico and in vitro data for the inhibitors and their relevance to drug discovery and future prospects for antimalarial drugs.

Marli Botha © CSIR PfGST as a drug target P. falciparum contains only one isoform of the detoxification enzyme GST. PfGST detoxifies endogenous and other xenobiotic compounds (Liebau et al., 2002). The glutathione and thioredoxin system forms the basis of cellular antioxidant defense in Plasmodium species. The hypothesis is that PfGST inhibitors would have antimalarial effect independently. But also, work in synergy with other antimalarial drugs (Platel et al., 1999).

Marli Botha © CSIR In silico screening data for commercially available compounds In silico prediction: GTX > NDA > LAP > EDP

Marli Botha © CSIR Preliminary Inhibition Assays In vitro results: GTX > NDA > LAP > EDP

Marli Botha © CSIR Conclusion Proof of Principle: This approach can be used to design ligands that bind PfGST and predict a consensus score that can be used to rank these ligands according to their affinity for PfGST. In silico methodology could be developed to form a pipe- line that scientists can use to obtain a library of ranked scaffolds for future drug design. It provided chemical scaffolds for PfGST for future antimalarial drug development.

Marli Botha © CSIR Future Prospects WISDOM (Wide In-Silico Docking On Malaria) An initiative which is led by Professor Vincent Breton of the Laboratoire de Physique Corpusulaire, Universite Blaise Pascal, Clermont-Ferrand, France, it was decided to use the malaria protein glutathione-S-transferase (GST) as a model system for the virtual screening of a 4.6 million compound library using grid computing. The current FlexX screening programme is based on the curation of the target active site as a rigid body. It does, however, allow for ligand conformational flexibility. Professor Breton’s team is currently trying to implement the use of the AMBER forcefield in conjunction with the FlexX docking protocol. This will allow for molecular dynamics to be done in conjunction with the docking.

Marli Botha © CSIR Acknowledgements Supervisors Prof AI Louw (Bioschemistry,UP), Prof F Joubert (Bioinformatics,UP) and Prof CP Kenyon (CSIR). CSIR and University of Pretoria for bursaries. Prof E Liebau (Bernhard Nocht Institute for Tropical Medicine – Hamburg,Germany) for providing the pJC20-PfGST high copy expression plasmid. My fellow students and scientist for all their valued advice, insight and useful discussions.

“A mouse is an animal that, if killed in sufficiently many and creative ways, will generate a PhD.”